
Mirabovak 50mg Tablet ER
Marketer
Devak Formulations
Salt Composition
Mirabegron (50mg)
Overview Mirabovak 50mg Tablet ER
Extended-release Mirabovak 50mg tablets alleviate overactive bladder symptoms such as urinary frequency, urgency, and incontinence. This medication relaxes bladder muscles, improving urine storage capacity. Always adhere to your physician's prescribed dosage and duration for Mirabovak 50mg ER. It may be taken with or without food; swallow the tablet whole, avoiding crushing or chewing. Discontinue use only after consulting your doctor, as abrupt cessation may exacerbate symptoms. Complete the prescribed treatment course for optimal results. Potential side effects include, but are not limited to, constipation, headache, hypertension, rhinitis, urinary tract infections, tachycardia, and arthralgia. Report any persistent or bothersome side effects to your doctor promptly. Prior to commencing treatment, disclose all current medications and pre-existing health conditions, including pregnancy or breastfeeding status. Individuals with hepatic or renal impairment require careful monitoring and regular check-ups as directed by their physician.
Uses of Mirabovak 50mg Tablet ER
Managing symptoms associated with overactive bladder
Major Benefits of Mirabovak 50mg Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 50mg Mirabovak extended-release tablet whole; avoid crushing, chewing, or breaking it. While consumption with or without food is acceptable, consistent timing is recommended.
Common Side effects of Mirabovak 50mg Tablet ER:
- Constipation
- Headache
- High blood pressure
- Nasal inflammation
- Urinary tract infection
- Fast heart rate
- Joint pain
How to use Mirabovak 50mg Tablet ER:
Administer this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Mirabovak 50mg Extended-Release Tablet can be consumed with or without food, though consistent timing is recommended.
How Mirabovak 50mg Tablet ER works:
Extended-release Mirabovak 50mg tablets function as a beta-3 adrenergic agonist. Their mechanism involves stimulating bladder beta-3 receptors, leading to detrusor muscle relaxation and a consequent reduction in urinary urgency, frequency, and incontinence.
SAFETY ADVICE
AlcoholCAUTION
Use of Mirabovak 50mg Extended-Release Tablets with alcohol requires careful consideration. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Extended-release Mirabovak 50mg tablets may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescription. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Mirabovak 50mg tablets are likely not safe for use while breastfeeding. Available evidence from humans indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Mirabovak 50mg Extended-Release Tablets.
KidneyCAUTION
Extended-release Mirabovak 50mg tablets require careful administration for individuals with advanced renal impairment. Dosage modification of Mirabovak 50mg extended-release tablets may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with liver impairment should use Mirabovak 50mg Extended-Release Tablets cautiously, potentially requiring dosage modification. Consult a physician for guidance. Mirabovak 50mg Extended-Release Tablets are contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Mirabovak 50mg Tablet ER :
Should you forget a Mirabovak 50mg Extended-Release Tablet, take it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Mirabovak 50mg Tablet ER
| Label | Value |
|---|---|
| Chemical Category | Anilide-based compound |
| Developing Habits | No. |
| Treatment Category | Urology |
| Actions | Beta-3 agonist for bladder control |
